Laflunimus

Laflunimus (HR325) 是一种免疫抑制剂和 Leflunomide 活性代谢物 A771726 的类似物。Laflunimus 是一种口服的二氢硼酸脱氢酶 (DHODH) 抑制剂。Laflunimus 抑制免疫球蛋白 (Ig) 分泌，抑制 Ig M 和 IgG 分泌的 IC50 值分别为 2.5 和 2 μM。Laflunimus 也是前列腺素内过氧化物合酶 (PGHS) -1 和 -2 抑制剂。

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
5mg

￥3262.00

2610.00

- +
10mg

￥5175.00

4140.00

- +
50mg

￥12825.00

10260.00

- +
100mg

￥19237.00

15390.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

Background

Laflunimus (HR325) is an immunosuppressive agent and an analogue of the Leflunomide-active metabolite A77 1726. Laflunimus is an orally active inhibitor of dihydroorotate dehydrogenase (DHODH). Laflunimus suppresses immunoglobulin (Ig) secretion, with IC50 values of 2.5 and 2 µM for IgM and IgG, respectively. Laflunimus also is a prostaglandin endoperoxide H synthase (PGHS) -1 and -2 inhibitor[1][2].

[1]. Thomson TA, et al. In vitro and in Vivo inhibition of immunoglobulin secretion by the immunosuppressive compound HR325 is reversed by exogenous uridine. Scand J Immunol. 2002 Jul;56(1):35-42. [2]. Curnock AP, et al. Potencies of leflunomide and HR325 as inhibitors of prostaglandin endoperoxide H synthase-1 and -2: comparison with nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther. 1997 Jul;282(1):339-47.